Literature DB >> 3494659

Efforts to produce human cytotoxic T-cell hybridomas by electrofusion and PEG fusion.

C Gravekamp, D Santoli, R Vreugdenhil, J G Collard, R L Bolhuis.   

Abstract

Cytotoxic human T cells from different sources were fused with different types of human T-lymphoma cells and mouse B-myeloma cells using variations of the polyethylene glycol (PEG) method and electrofusion. Both techniques yielded proliferating hybridomas. The frequency of wells with proliferating hybridomas depended on the tumor fusion partner used; the best results were obtained with HSB-1, whereas fusions with JURKAT-1 and HPB-1 did not yield any hybridomas. For one tumor cell line (HSB-1), considerably more hybridomas were obtained with electrofusion than with the PEG fusion (with or without heat shock). There was no consistent relationship between the presence or absence of cytotoxic activity of the T lymphocytes against the tumor fusion partner and the yield of hybridomas. In human-human as well as in human-mouse hybridomas most of the lymphocyte derived chromosomes were lost. Four of the more than 600 hybridomas tested showed transient cytotoxic activity, but in none of them this function could be immortalized. Two of the hybridomas obtained with CEM-1 as tumor fusion partner expressed low levels of lymphocyte-derived CD3 antigens. Two hybridomas obtained with HSB-1 were highly invasive in vitro in rat hepatocyte cultures, whereas HSB-1 tumor cells were not.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3494659     DOI: 10.1089/hyb.1987.6.121

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  2 in total

1.  Electrofusion of osmotically treated cells. High and reproducible yields of hybridoma cells.

Authors:  J J Schmitt; U Zimmermann; P Gessner
Journal:  Naturwissenschaften       Date:  1989-03

2.  Conditioned medium from gerbil--mouse T cell heterohybridomas improved antibody secretion.

Authors:  Takao Ukaji; Masako Hashimoto; Osamu Kai
Journal:  Exp Anim       Date:  2015-02-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.